[Skip to Content]

Upstate Active Clinical Trials

Study Title:

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

What is the purpose of the study?

The researchers performing the CO-338-052 study will be evaluating whether rucaparib is a good treatment option in subjects with prostate cancer, and who have mutations in BRCA, ATM, or other DNA-repair genes.

Upstate Institutional Review Board (IRB) Number:

1012698

Study/Protocol ID:

CO-338-052

Study Phase:

PHASE II

Patient Age Group:

Adults

Principal Investigator:

Bernard J Poiesz, MD

What is involved if I participate?

  • How long is the study?
    The study is expected to last 4 years with individual participants expected to be treated and followed for about a year. The study has optional consent for continuing treatment with rucaparib following disease progression.
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Biomarker testing of archival tumor tissue and blood, physical exams, blood tests,ECGs, CT and bone scans, questionnaires.

Where will the study take place?

This study will take place at SUNY Upstate Medical University Cancer Center. The satellite sites will only be used for consenting. All other study procedures are to be performed at the Cancer Center.

ClinicalTrials.Gov ID:

NCT02952534

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Patricia M Benz
Phone: 315-464-8253
Email: benzp@upstate.edu

Return to Previous Page || Search Again

Top